The American Cancer Society (ACS) updates its colorectal cancer screening recommendations to expand options beyond colonoscopy. In guidance published May 27 in CA: A Cancer Journal for Clinicians, the ACS maintains its recommendation that average-risk adults begin screening at age 45 and that colonoscopy is done every 10 years. The update adds new non-colonoscopy tests intended to increase participation and reduce barriers to screening as colorectal cancer rates continue to rise in adults under 50.

The ACS includes blood-based screening as a new option: a test branded Shield, approved by U.S. regulators in 2024, that looks for tumor DNA in a blood sample. The ACS also lists two stool-based tests for at-home use. One, branded Cologuard, analyzes stool for DNA and hemoglobin markers. The other, branded ColoSense, analyzes stool for RNA and hemoglobin markers. The guidance states stool tests have higher effectiveness than the blood test and recommends blood testing mainly for people who decline or cannot use other options.

Across sources, experts note colonoscopy remains the “gold standard,” but more alternatives may help more people get screened. The ACS advises that any positive stool- or blood-test result be followed by colonoscopy within 6 months.